Aptar Digital Health has entered into a partnership with Enable Injections, Inc. to provide a companion digital platform that will run alongside Enable’s enFuse® On‑Body Delivery System. The platform will guide patients and caregivers through the injection process, capture treatment data, and offer training modules, patient‑reported outcomes, and symptom tracking. By integrating digital support with a large‑volume biologic delivery device, Aptar expands its digital health footprint and creates a new recurring revenue stream that complements its existing drug‑delivery component business.
The enFuse® system is a wearable device designed for subcutaneous administration of large‑volume (5–25 mL) and high‑viscosity therapeutics. The companion solution will capture real‑world data, provide analytics dashboards, and deliver actionable insights for clinical development, launch readiness, and real‑world use. This integration supports pharmaceutical partners in extending the value of their therapies beyond delivery, improving adherence and patient outcomes.
"This collaboration seeks to enhance the treatment experience of patients beyond the moment of injection. Together, we will combine innovative drug delivery with digital support tools. This can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient's journey," said Michael D. Hooven, Chairman and CEO of Enable Injections. "We are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life. Large‑volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long‑term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self‑administration," added Damien McKeon, SVP Strategic Partnerships at Aptar Digital Health. "The enFuse companion solution reflects our vision of a more connected treatment experience that supports patients beyond the moment of injection," Hooven added.
The partnership follows a strong fourth‑quarter 2025 performance for AptarGroup, Inc., which reported earnings per share of $1.25 versus a forecast of $1.23 and revenue of $963 million versus an anticipated $878.58 million. The new digital health collaboration is part of Aptar’s broader strategy to capture recurring revenue, deepen relationships with pharmaceutical customers, and position the company as a leader in connected drug delivery and patient support solutions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.